Inflammatory suppressive effect of prostate cancer cells with prolonged exposure to transforming growth factor β on macrophage-differentiated cells via downregulation of prostaglandin E2

Oncology Letters

Volumn 8, Issue 4, 2014, Pages 1513-1518

  Hayashi, Akinobu ^a   Hirokawa, Yoshifumi S ^a   Kagaya, Michiko ^a   Fujiwara, Masaya ^a   Yoneda, Misao ^b   Kanayama, Kazuki ^a   Uchida, Katsunori ^a   Ishii, Kenichiro ^a   Shiraishi, Taizo ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Microenvironment; Prostate cancer; THP 1 macrophage; Transforming growth factor 1

Indexed keywords

CYCLOOXYGENASE 2; GROWTH FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOLIPASE C; PROSTAGLANDIN E2; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MACROPHAGE; MRNA EXPRESSION ASSAY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

EID: 84919682496     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2402     Document Type: Article

References (37)

1. Yingling JM, Blanchard KL and Sawyer JS: Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3: 1011-1022, 2004.
2. Eastham JA, Truong LD, Rogers E, et al: Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73: 628-635, 1995.
3. Kim IY, Ahn HJ, Zelner DJ, et al: Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res 56: 44-48, 1996.
4. Wilding G, Zugmeier G, Knabbe C, Flanders K and Gelmann E: Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 62: 79-87, 1989.
5. Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30: 3-21, 2000.
6. Zha S, Gage WR, Sauvageot J, et al: Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61: 8617-8623, 2001.
7. Gupta S, Srivastava M, Ahmad N, Bostwick DG and Mukhtar H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73-78, 2000.
8. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
9. Hagemann T, Wilson J, Kulbe H, et al: Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175: 1197-1205, 2005.
10. Qian B, Deng Y, Im JH, et al: A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 4: e6562, 2009.
11. Lissbrant IF, Stattin P, Wikstrom P, et al: Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 17: 445-451, 2000.
12. Denardo DG, Brennan DJ, Rexhepaj E, et al: Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67, 2011.
13. Qian BZ and Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51, 2010.
14. Hirokawa YS, Takagi A, Uchida K, et al: High level expression of STAG1/PMEPA1 in an androgen-independent prostate cancer PC3 subclone. Cell Mol Biol Lett 12: 370-377, 2007.
15. Wrana JL, Attisano L, Cárcamo J, et al: TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014, 1992.
16. Park BJ, Park JI, Byun DS, Park JH and Chi SG: Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res 60: 3031-3038, 2000.
17. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002.
18. El Fiky A, Perreault R, McGinnis GJ and Rabin RL: Attenuated expression of interferon-βand interferon-λ1 by human alternatively activated macrophages. Hum Immunol 74: 1524-1530, 2013.
19. Wu TH, Li YY, Wu TL, Chang JW, Chou WC, Hsieh LL, Chen JR and Yeh KY: Culture supernatants of different colon cancer cell lines induce specific phenotype switching and functional alteration of THP-1 cells. Cell Immunol 290: 107-115, 2014.
20. Danielsen PH, Møller P, Jensen KA, Sharma AK, Wallin H, Bossi R, Autrup H, Mølhave L, Ravanat JL, Briedé JJ, et al: Oxidative stress, DNA damage, and inflammation induced by ambient air and wood smoke particulate matter in human A549 and THP-1 cell lines. Chem Res Toxicol 24: 168-184, 2011.
21. Daigneault M, Preston JA, Marriott HM, Whyte MK and Dock rell DH: The identification of markers of macrophage dif ferentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 5: e8668, 2010.
22. Tsagozis P, Eriksson F and Pisa P: Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunother 57: 1451-1459, 2008.
23. Spiotto MT and Chung TD: STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42: 88-98, 2000.
24. Smith PC, Hobisch A, Lin DL, Culig Z and Keller ET: Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12: 33-40, 2001.
25. Kamimoto M, Mizuno S and Nakamura T: Reciprocal regulation of IL-6 and IL-10 balance by HGF via recruitment of heme oxygenase-1 in macrophages for attenuation of liver injury in a mouse model of endotoxemia. Int J Mol Med 24: 161-170, 2009.
26. Donnelly RP, Crofford LJ, Freeman SL, et al: Tissue-specific regulation of IL-6 production by IL-4. Differential effects of IL-4 on nuclear factor-kappa B activity in monocytes and fibroblasts. J Immunol 151: 5603-5612, 1993.
27. Williams JA, Pontzer CH and Shacter E: Regulation of macrophage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E 2: the role of p38 mitogen-activated protein kinase. J Interferon Cytokine Res 20: 291-298, 2000.
28. Meulmeester E and Ten Dijke P: The dynamic roles of TGF-β1 in cancer. J Pathol 223: 205-218, 2011.
29. Moustakas A and Heldin CH: Non-Smad TGF-beta signals. J Cell Sci 118: 3573-3584, 2005.
30. Lin X, Duan X, Liang YY, et al: PPM1A functions as a Smad phosphatase to terminate TGFbetasignaling. Cell 125: 915-928, 2006.
31. Chen HB, Shen J, Ip YT and Xu L: Identification of phosphatases for Smad in the BMP/DPP pathway. Genes Dev 20: 648-653, 2006.
32. Sapkota G, Knockaert M, Alarcón C, et al: Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-betapathways. J Biol Chem 281: 40412-40419, 2006.
33. Gao S, Alarcón C, Sapkota G, et al: Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol Cell 36: 457-468, 2009.
34. Bissell MJ and Radisky D: Putting tumours in context. Nat Rev Cancer 1: 46-54, 2001.
35. Yan M, Rerko RM, Platzer P, et al: 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 101: 17468-17473, 2004.
36. Hagemann T, Lawrence T, McNeish I, et al: 'Re-educating' tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205: 1261-1268, 2008.
37. Mani SA, Guo W, Liao MJ, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.